Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.
News and updates on AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) focus on its role as a therapeutic acute wound care company centered on the RECELL System and related wound care technologies. Company news frequently highlights developments in thermal burn and trauma treatment, clinical evidence for its products, and regulatory milestones in key markets.
Investors following RCEL news can expect coverage of financial results, revenue updates, and capital structure actions such as credit agreements and equity placements, as disclosed in Form 8-K filings and press releases. AVITA Medical regularly reports quarterly and annual financial performance, adjustments to revenue outlook, and steps taken to align operating expenses with its growth priorities.
News flow also includes clinical and scientific updates. AVITA Medical has reported data presentations at medical conferences, including systematic reviews of peer-reviewed literature and real-world registry analyses supporting the RECELL System in acute wound treatment. These items describe outcomes such as reduced donor site burden, faster healing, shorter hospital stays, and favorable economic impact in burn care.
Regulatory and market access developments are another recurring theme. The company has announced CE Mark approval for RECELL GO under the EU Medical Device Regulation, regulatory clearances for RECELL in Europe, Australia, and Japan, and support from Australia’s Medical Services Advisory Committee for the use of autologous skin cell suspension prepared with RECELL in severe burns. Corporate governance updates, such as board appointments and executive transitions, are also disclosed through AVITA Medical’s news releases.
For readers tracking RCEL, this news stream provides insight into the company’s clinical progress, regulatory status, financial performance, and leadership changes, all of which shape its position in the acute wound care and medical device landscape.
AVITA Medical (NASDAQ: RCEL) reported strong financial results for Q3 FY2021, with RECELL® revenue reaching $8.8 million, up 126% year-over-year. Procedural volumes rose to 492 from 408 in Q3 2020, with 99 burn center accounts now in use. The company trained 244 burn surgeons, achieving an 81% penetration rate. Despite a net loss of $6.0 million, down from $15.0 million last year, and operating expenses decreasing to $13.2 million, gross margin fell to 76% due to lower pricing from BARDA contracts. The company expects Q4 revenue between $8.2-$8.6 million.
AVITA Medical (NASDAQ: RCEL) announced plans to release its fiscal Q3 2021 financial results on May 13, 2021, post market close. A conference call and webcast will follow at 1:30 PM PT to discuss these results alongside recent company highlights. AVITA specializes in regenerative medicine, utilizing its patented RECELL System for autologous skin restoration in treating burns and chronic wounds. The system has shown clinical advancements and is FDA approved, enhancing treatment efficacy and reducing donor skin requirements.
AVITA Medical announced the acceptance of nine abstracts at the 43rd Annual John A. Boswick Burn & Wound Care Symposium, highlighting the clinical and cost-effectiveness of the RECELL System in treating burns. The symposium will take place from April 17-22, 2021, in Maui, Hawaii. CEO Dr. Mike Perry emphasized the system's versatility in treating varying burn depths and its benefits when combined with other surgical technologies. Data from randomized clinical trials and real-world use support the RECELL System as a significant advancement in burn treatment.
AVITA Medical (NASDAQ: RCEL) announced the acceptance of 15 abstracts showcasing the benefits of its RECELL System at the American Burn Association's upcoming annual meeting. This marks the highest number of presentations since the RECELL's FDA approval in 2018. Over 80% of U.S. burn surgeons are now certified in using the system, which demonstrates a growing adoption in treating diverse burn injuries. The findings emphasize both clinical outcomes and cost-effectiveness, supporting the RECELL System as a significant advancement in burn care.
AVITA Medical (Nasdaq: RCEL) has appointed Michael Holder as Chief Financial Officer effective March 22, 2021. Mr. Holder brings over 25 years of finance experience, previously serving as CFO at ImmuneCyte and CEO at Carolina Longevity Institute. His role will encompass global finance, accounting, M&A, and investor relations. CEO Dr. Mike Perry emphasized Holder's experience will enhance the leadership team. AVITA Medical focuses on regenerative medicine addressing burns and chronic wounds through its RECELL® System, FDA-approved since September 2018.
AVITA Medical, Inc. (Nasdaq: RCEL) has successfully completed an underwritten public offering, issuing 3,214,250 shares at US$21.50 each, totaling approximately US$69.1 million in gross proceeds. This includes shares from the underwriters' full exercise of their option to purchase additional stock. The funds will support product development and regulatory approvals. The offering was made under a previously filed shelf registration statement with the SEC. AVITA Medical is focused on regenerative medicine technologies, particularly the RECELL System for skin restoration.
AVITA Medical announced a registered public offering of 2,795,000 shares at a price of US$21.50 per share, potentially raising gross proceeds of approximately US$60.1 million. The underwriters have a 30-day option to purchase an additional 419,250 shares. The funds will be utilized for product development, seeking approvals for additional indications, and general corporate purposes. The offering is expected to close on March 1, 2021, subject to customary conditions.
AVITA Medical has announced an underwritten public offering of its common stock, with a possibility for underwriters to purchase an additional 15% of shares sold. The offering is subject to market conditions and aims to fund product development, seek additional approvals, and cover general corporate purposes. The company has previously filed a registration statement with the SEC, and joint book-running managers for the offering include Piper Sandler & Co. and Cowen and Company. AVITA Medical is known for its RECELL System, which provides innovative skin restoration treatments.
AVITA Medical, operating under ticker RCEL, will present at two upcoming investor conferences: the Cowen 41st Annual Healthcare Conference on March 4, 2021, and the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021. Both presentations will be accessible via live audio webcasts on their investor relations website. AVITA focuses on regenerative medicine with the RECELL® System, designed for treating burns using a patient's own skin cells. The system was FDA-approved in September 2018, addressing significant clinical needs effectively.
AVITA Medical, Inc. (NASDAQ: RCEL) reported a strong second quarter for fiscal year 2021, ending December 31, 2020, with U.S. RECELL® revenue at $5.0 million, up 62% year-over-year. Total global revenue reached $5.1 million, a 57% increase from the previous year. The gross margin improved to 84%, driven by extended shelf-life and lower shipping costs. Operating expenses decreased to $10.4 million. Despite a net loss of $5.6 million, the company held cash reserves of $59.8 million. Due to COVID-19 uncertainties, the company did not provide future financial guidance.